Wuhan New Coronary Inactivated Vaccine Launched
Science and Technology Daily, Wuhan, February 28 (Reporter Liu Zhiwei) On the morning of the 28th, the launch of the new crown inactivated vaccine from the Wuhan Institute of Biological Products of Sinopharm Group and the unveiling of the Central China Biological Industry Base were held in Wuhan.
The new crown inactivated vaccine jointly developed by the Wuhan Institute of Biological Products of China Biologics and the Institute of Virology of the Chinese Academy of Sciences was officially launched. This is the second new crown vaccine approved by China Biotechnology for conditional marketing.
After the outbreak of the new crown pneumonia, on February 1, 2020, China Biosciences, as the lead unit, won the emergency approval of the key special "2019-nCoV inactivated vaccine" project of the Ministry of Science and Technology National Key Research and Development Program "Public Safety Risk Prevention and Control and Emergency Technology and Equipment" .
The Wuhan Institute of Biological Products of China National Biology and the Wuhan Institute of Virology of the Chinese Academy of Sciences quickly launched the research and development of the new coronavirus inactivated vaccine.
The research team has successively conquered a series of key technologies for the development, production and quality control of new crown vaccines, including vaccine strain screening, virus seed library establishment, antibody preparation and identification, detection method establishment, compatibility and formulation screening, production process research, etc., and determined process technology routes and products Quality attributes, carried out and completed animal experiments and safety and effectiveness evaluations.
In March 2020, the new crown vaccine research and development laboratory and production workshop complex started construction at the Institute of Biology. After more than 100 days and nights, it covers an area of 7,260 square meters and has the capacity to produce 100 million doses of new coronavirus inactivated vaccines per year. Completed the R&D laboratory and production workshop complex.
This project provides a safe and reliable hardware guarantee for the scientific research and large-scale production of the new coronavirus inactivated vaccine.
It is reported that since July 16, 2020, the Wuhan Institute of Biological Products of China has carried out the "New Coronary Inactivated Vaccine Phase III Clinical Trial" in the UAE and other countries. The trial adopts "international multi-center, randomized, double-blind, Placebo Parallel Control Design".
The results of the interim analysis of the Phase III clinical trial showed that it meets the relevant technical standards of the World Health Organization and the relevant standards in the "Guidelines for Clinical Evaluation of New Coronavirus Preventive Vaccines (Trial)" issued by the State Food and Drug Administration.
On the same day, the Central China Biological Industry Base was unveiled simultaneously.
According to Duan Kai, director of the Wuhan Institute of Biological Products of China Biology, the base is mainly based on the implementation of the Wuhan Institute of Biological Products. There are three directions as a whole. The first is vaccines, the second is blood preparations, and the third One is therapeutic biological drugs.
China National Biotech will build this base into a modernized biopharmaceutical industrialization base. It plans to develop 7-10 new products and realize the industrialization of these products.